LONHALA MAGNAIR Rx
Generic Name and Formulations:
Glycopyrrolate 25mcg/mL; oral soln for inhalation.
RECENT UPDATESMonograph added.
Indications for LONHALA MAGNAIR:
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
For oral inhalation use only with Magnair device. Administer at the same time of the day (AM + PM). Inhale contents of one vial (25mcg) twice daily.
Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Labor & delivery. Pregnancy. Nursing mothers.
Additive effects with concomitant other anticholinergic-containing drugs; avoid.
Dyspnea, urinary tract infection, wheezing, upper respiratory tract infection, nasopharyngitis, peripheral edema, fatigue; paradoxical bronchospasm, hypersensitivity reactions.
Kit—60 vials (w. one Magnair device)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR
- Breast Cancer: Determining the Best Diet for Disease Prevention
- Hormone Therapy for Breast Cancer May Cause Diabetes
- Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers
- Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma